NASHTARGET | Validation of a new drug target in non-alcoholic steatohepatitis

Summary
This research focuses on the increasing prevalence of metabolic liver disease, specifically non-alcoholic steatohepatitis (NASH), which is driven by obesity, diabetes, and its related causal connections. NASH is a significant medical challenge with no approved treatments, causing a substantial economic burden. The project aims to investigate the role of oxidative stress in NASH development and progression. By targeting the MAP kinases p38 and JNK, which drive the inflammatory and fibrotic aspects of NASH, our research could lead to new treatment approaches.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/101123183
Start date: 01-06-2023
End date: 30-11-2024
Total budget - Public funding: - 150 000,00 Euro
Cordis data

Original description

This research focuses on the increasing prevalence of metabolic liver disease, specifically non-alcoholic steatohepatitis (NASH), which is driven by obesity, diabetes, and its related causal connections. NASH is a significant medical challenge with no approved treatments, causing a substantial economic burden. The project aims to investigate the role of oxidative stress in NASH development and progression. By targeting the MAP kinases p38 and JNK, which drive the inflammatory and fibrotic aspects of NASH, our research could lead to new treatment approaches.

Status

SIGNED

Call topic

ERC-2023-POC

Update Date

12-03-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon Europe
HORIZON.1 Excellent Science
HORIZON.1.1 European Research Council (ERC)
HORIZON.1.1.0 Cross-cutting call topics
ERC-2023-POC ERC PROOF OF CONCEPT GRANTS
HORIZON.1.1.1 Frontier science
ERC-2023-POC ERC PROOF OF CONCEPT GRANTS